Pasar al contenido principal

FARMACOLOGIA HUMANA DE DIFERENTES PREPARADOS DE CANNABIS ADMINISTRADOS POR DISTINTAS VIAS Y LA INFLUENCIA DEL GENERO.

PI20/00804

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Centro realización INSTITUTO DE INVESTIGACION GERMANS TRIAS I PUJOL (IGTP)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans

  • Caicedo di Filippo, Dolly Andrea|||0009-0009-6523-0265
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Papaseit, Esther|||0000-0003-2620-4274
Cannabis is the most commonly used illicit substance worldwide. Recent years have seen an increase in cannabis consumption, and with new approvals and therapeutic indications, there are challenges in minimizing the risks and interactions between cannabis-based products, cannabis prescription drugs, other approved prescription drugs, and other substances of abuse. Thus, identifying the enzymes metabolizing cannabinoid drugs and their relationship with other prescription drugs is crucial for understanding the potential interactions and effects of their simultaneous use. This article offers a comprehensive review of cannabis and the pharmacokinetic interactions between cannabis products, cannabis prescription drugs, and other approved prescription drugs, as well as other substances of abuse. It also compiles existing evidence of these interactions and describes the clinical outcomes associated with the inhibition or induction of various enzymes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Antidepressant Drugs and COVID-19, A Review of Basic and Clinical Evidence

  • Mas, Marta
  • García-Vicente, Juan Antonio
  • Estrada-Gelonch, Anaïs
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Papaseit, Esther|||0000-0003-2620-4274
  • Torrens, Marta|||0000-0001-6222-4761
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
The COVID-19 pandemic has encouraged the repurposing of existing drugs as a shorter development strategy in order to support clinicians with this difficult therapeutic dilemma. There is evidence to support the theory that some antidepressants can reduce concentrations of different cytokines in humans and animals and, recently, the antiviral activity of some antidepressants against SARS-CoV-2 has been reported. The aims of this narrative review are to evaluate the possible role of antidepressants in the treatment of COVID-19 infection and the possible benefits and risks of patients taking antidepressants for mental disorders and COVID-19 infection. A review was performed to analyse the current literature to identify the role of antidepressant medication in the treatment of COVID-19 patients. The electronic search was completed in MEDLINE and MedRxiv/BioRxiv for published literature and in ClinicalTrials.gov for ongoing clinical trials. The results show some evidence from preclinical data and observational studies about the possible efficacy of some specific antidepressants for treating COVID-19 infection. In addition, two published phase II studies testing fluvoxamine showed positive results for clinical deterioration and hospitalization rate versus a placebo. Seven ongoing clinical trials testing fluvoxamine, fluoxetine, and tramadol (as per its anti-inflammatory and antidepressant effect) are still in the early phases. Although the available evidence is limited, the sum of the antiviral and anti-inflammatory preclinical studies and the results from several observational studies and two phase II clinical trials provide the basis for ongoing clinical trials evaluating the possible use of antidepressants for COVID-19 infection in humans. Further investigations will be needed to support the possible use of antidepressants for this application.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Synthetic cannabinoids use in a sample of opioid-use disorder patients

  • Alías Ferri, María|||0000-0002-2237-8392
  • Pellegrini, Manuela|||0000-0003-3348-5297
  • Marchei, Emilia|||0000-0002-7158-6032
  • Pacifici, Roberta
  • Rotolo, Maria Concetta
  • Pichini, Simona
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Papaseit, Esther|||0000-0003-2620-4274
  • Muga, Roberto|||0000-0001-6301-431X
  • Fonseca, Francina|||0000-0002-0779-6545
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Torrens, Marta
Cannabis is the most widely consumed illegal drug in the world and synthetic cannabinoids are increasingly gaining popularity and replacing traditional cannabis. These substances are a type of new psychoactive substance that mimics the cannabis effects but often are more severe. Since, people with opioids use disorder use widely cannabis, they are a population vulnerable to use synthetic cannabinoids. In addition, these substances are not detected by the standard test used in the clinical practice and drug-checking is more common in recreational settings. A cross-sectional study with samples of 301 opioid use disorder individuals was carried out at the addiction care services from Barcelona and Badalona. Urinalysis was performed by high-sensitivity gas chromatography-mass spectrometry (GC-MS) and ultra-high-performance liquid chromatography-high -resolution mass spectrometry (UHPLC-HRMS). Any synthetic cannabinoid was detected in 4.3% of the individuals and in 23% of these samples two or more synthetic cannabinoids were detected. Among the 8 different synthetic cannabinoids detected, most common were JWH-032 and JWH-122. Natural cannabis was detected in the 18.6% of the samples and only in the 0.7% of them THC was identified. Several different synthetic cannabinoids were detected and a non-negligible percentage of natural cannabis was detected among our sample. Our results suggest that the use of synthetic cannabinoids may be related to the avoidance of detection. In the absence of methods for the detection of these substances in clinical practice, there are insufficient data and knowledge making difficult to understand about this phenomenon among opioid use disorder population.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

New Psychoactive Substances Consumption in Opioid-Use Disorder Patients

  • Alías Ferri, María|||0000-0002-2237-8392
  • Pellegrini, Manuela|||0000-0003-3348-5297
  • Marchei, Emilia|||0000-0002-7158-6032
  • Pacifici, Roberta
  • Rotolo, Maria Concetta
  • Pichini, Simona
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Papaseit, Esther|||0000-0003-2620-4274
  • Muga, Roberto|||0000-0001-6301-431X
  • Fonseca, Francina|||0000-0002-0779-6545
  • Torrens, Marta
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
Background: Since the beginning of the 21st century, the large number and wide chemical variety of new psychoactive substances (NPS) that enter the market every year has become a public health problem. Given the rapidity with which the drug market is changing, many NPS are not clinically investigated and their effects and health risks are unknown. Drug testing is a very useful tool for this purpose, but, unfortunately, it is not very widespread in individuals with opioid-use disorder under detoxification treatment. The aim of this study is to investigate the use of illicit drugs and NPS in opioid-use disorder (OUD) patients on opioid agonist treatment. (2) Methods: A multicenter, descriptive, cross-sectional study was conducted at two addiction care services in Barcelona and Badalona, Spain. Urine samples were collected from OUD individuals attending these two centers, who anonymously donated a urine sample at the time of a periodical visit. Samples were analyzed by high-sensitivity gas chromatography-mass spectrometry (GC-MS) and ultra-high-performance liquid chromatography-high -resolution mass spectrometry (UHPLC-HRMS). (3) Results: Out of the 187 collected and analyzed urine samples, 27.3% were positive for any type of NPS and 8.6% were positive for new synthetic opioids, including fentanyl and its derivatives (NSO). Other frequently detected substances were benzodiazepines in 46.0% of samples, antipsychotics in 27.8% of samples, or cocaine and cannabis in 23.5% of samples. (4) Conclusion: A wide number of NPS, including NSO, have been detected in urine samples from an OUD population. A lack of NPS detection in standard drug screening among drug users can hide the identification of a potential public health problem.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Acute Pharmacological Effects and Oral Fluid Concentrations of the Synthetic Cannabinoids JWH-122 and JWH-210 in Humans After Self-Administration, An Observational Study

  • Martínez, Lucia|||0000-0002-2941-0922
  • La Maida, Nunzia|||0000-0003-0127-4225
  • Papaseit, Esther|||0000-0003-2620-4274
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Poyatos, Lourdes|||0000-0002-4641-8600
  • Pellegrini, Manuela|||0000-0003-3348-5297
  • Pichini, Simona
  • Ventura, Mireia|||0000-0003-1133-6872
  • Galindo, Liliana|||0000-0002-2396-4772
  • Busardo, Francesco Paolo|||0000-0002-3082-4532
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
Synthetic cannabinoids (SCs) are a group of new psychoactive drugs used recreationally with potential health risks. They are monitored by the EU Early Warning System since 2010 due to severe adverse effects on consumers. JWH-122 and JWH-210 are naphthoylindole SCs and potent cannabinoid receptor CB1 and CB2 agonists. Information about the effects of SCs usually is available from intoxication cases and surveys, and few studies on humans after controlled administration or observational/naturalistic studies using standardized measures of cardiovascular and subjective effects are available. The aim of this study was to evaluate the acute pharmacological effects of JWH-122 and JWH-210 recreational consumption in a 4 h observational study and assess their disposition in oral fluid (OF). Sixteen volunteers self-administered 1 mg dose of JWH-122 (n = 8) or 2.25 mg mean dose of JWH-210 (range 2-3 mg, n = 8) by inhalation (smoking). Physiological parameters including blood pressure (systolic and diastolic), heart rate (HR), and cutaneous temperature were measured. A set of visual analog scales, the 49-item short-form version of the Addiction Research Center Inventory (ARCI), and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) were used for the evaluation of subjective effects. OF was collected at baseline and at 10, 20, and 40 min and 1, 2, 3, and 4 h after self-administration. Statistically significant increases in systolic blood pressure (SBP), diastolic blood pressure (DBP), and HR were observed after JWH-122 self-administration but not after JWH-210 self-administration. JWH-210 self-administration produced significant changes in subjective drug effects, similar to those induced by THC (intensity, high, good effects, and hunger). The subjective effects following JWH-122 consumption were minimal. The maximal effects were mostly observed 20 min after intake. JWH-122 and JWH 210 OF concentration reached a peak 20 min after administration and could not be detected after 3 h. The results demonstrated a different pattern of effects of these two SCs. Due to the limitations of our observational study, further research with a larger sample and controlled studies are needed to better define the acute pharmacological effect and health risk profile of JWH-122 and JWH-210.